FibroGen (NASDAQ:FGEN) reported Q2 EPS of ($0.78), $0.14 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $36.16 million.
FibroGen (NASDAQ:FGEN) reported Q2 EPS of ($0.78), $0.14 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $36.16 million.